Compare FSK & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSK | VERA |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 2008 | 2021 |
| Metric | FSK | VERA |
|---|---|---|
| Price | $11.44 | $30.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $13.19 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 2.3M | 2.0M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 18.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $472.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.72 | $19.07 |
| 52 Week High | $20.41 | $56.05 |
| Indicator | FSK | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 59.40 | N/A |
| Support Level | $10.41 | N/A |
| Resistance Level | $11.22 | N/A |
| Average True Range (ATR) | 0.28 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 99.60 | 0.00 |
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.